Study Of SU011248 In Combination With Paclitaxel In Patients With Metastatic Breast Cancer

Completed · Phase 1

Conditions studied: Breast Neoplasms

In brief

This study is to evaluate the safety of SU011248 in combination with paclitaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.

Key facts

Study ID

NCT00174434

Run by

Pfizer

People needed

22

Starts

2005-09-01

Expected to finish

2007-08-01

Last updated by the study team

2009-01-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Breast cancer with evidence of unresectable, locally recurrent or metastatic disease.
• Candidate for treatment with paclitaxel.

You may not qualify if…

• Prior chemotherapy in the advanced disease setting.
• HER2 positive disease unless previously treated with trastuzumab.

Where it is running

• Pfizer Investigational Site — Harvey, Illinois, United States
• Pfizer Investigational Site — Harvey, Illinois, United States
• Pfizer Investigational Site — Indianapolis, Indiana, United States
• Pfizer Investigational Site — Indianapolis, Indiana, United States
• Pfizer Investigational Site — Munster, Indiana, United States
• Pfizer Investigational Site — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.